BioVaxys is a clinical stage biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma.
BioVaxys has raised $1.4M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.
BioVaxys's investors include THECCSGROUP, James Passin, Kenneth Kovan.
BioVaxys is headquartered in Etobicoke, Canada.
BioVaxys is a clinical stage biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma.
BioVaxys is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BioVaxys — Funding & Investors." VCBacked, October 7, 2025, https://www.vcbacked.co/company/biovaxys. Accessed August 14, 2026.
VCBacked. (2025). BioVaxys — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/biovaxys
{{cite web |title=BioVaxys — Funding & Investors |url=https://www.vcbacked.co/company/biovaxys |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated